World Well-Being ISO/FDA Natural Peptides Anticoagulant CAS 113274-56-9 Pharmaceuticals Leech Hirudin Powder 98% Leech Extract

• Customization: Available
• Certification: ISO, FDA, Halal
• Assay Method: HPLC, UV
• Application Form: Lotion, Tablet, Capsule
• Application: Food, Health Care Products, Medicine, Cosmetics
• State: Powder
• Extract Source: Leech
• Product Name: Leech Extract
• Appearance: White Powder
• Used Part: Leech
• Shelf Life: 2 Years
• Delivery Time: 7- 10days
• Sample: Available
• Transport Package: 1kg/Foil Bag, 25kgs/Drum
• Specification: Hirudin 98%
• Trademark: World Well-Being
• Origin: Hunan, China
• Production Capacity: 1000kgs/Month

Product Description

 

Hirudin is one of the most active components extracted from leech and its salivary gland. It is a small protein (polypeptide) composed of 65-66 amino acids. Leeches are rich in hirudin. Hirudin has a strong inhibitory effect on thrombin, which is the strongest natural specific inhibitor of thrombin. Hirudin has a strong effect of inhibiting blood coagulation and antithrombotic,
and has a broad application prospect in clinical treatment and prevention of various thrombosis.

 

Common Name	HIRUDIN
CAS Number	8001-27-2	Molecular Weight	7027
Density	N/A	Boiling Point	N/A
Molecular Formula	C287H440N80O110S6	Melting Point	N/A
MSDS	USA	Flash Point	N/A

Certificate of Analysis

Item	Specification	Result
Assay	99%	99.68%
Appearance	White Powder	conforms
Odor	Characteristic	conforms
Taste	Characteristic	conforms
Particle Size	NLT 100% Through 80 mesh	conforms
Loss on Drying	<2.0%	0.45%
Heavy metals
Total Heavy Metals	≤10ppm	conforms
Arsenic	≤3ppm	conforms
Lead	≤3ppm	conforms
Microbiological Tests
Total Plate Count	≤1000cfu/g	conforms
Total Yeast & Mold	≤100cfu/g	conforms
E.Coli	Negative	Negative
Salmonella	Negative	Negative

Function 

1.Animal studies and clinical studies have shown that hirudin is highly effective in anticoagulant, antithrombotic, and blocking of thrombin-catalyzed activation of blood coagulation factors and platelet response and other bloody phenomena.

2.In addition, it also inhibits thrombin-induced proliferation of fibroblasts and thrombin stimulation of endothelial cells. Compared with heparin, it not only uses less, does not cause hemorrhage, and does not depend on endogenous cofactors; heparin has the risk of causing hemorrhage and antithrombin III during the course of diffuse intravascular coagulation. It is often reduced, which will limit the efficacy of heparin, and the use of blisters will have a better effect.

Application
Hirudin is a promising anticoagulant and blood stasis drug, which can be used in the treatment of various thrombotic diseases, especially the treatment of venous thrombosis and diffuse vascular coagulation. It can also be used to prevent the formation of arterial thrombosis after surgical operation, and to prevent the formation of thrombosis after thrombus dissolution or vascular reconstruction. Improve extracorporeal blood circulation and hemodialysis process. Hirudin can promote wound healing in microsurgery, which often fails due to anastomotic vascular embolism. Hirudin has also been shown to play a role in cancer treatment. It can stop the metastasis of tumor cells, and has been shown to be effective in tumors such as fibrosarcoma, osteosarcoma, angiosarcoma, melanoma and leukemia. Hirudin can also be used in combination with chemotherapy and radiotherapy to enhance efficacy by promoting blood flow in the tumor.